Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now
Close

Ibnsina Pharma Co (ISPH)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.000 +0.050    +1.27%
22/02 - Closed. Currency in EGP ( Disclaimer )
  • Volume: 12,326,626
  • Bid/Ask: 4.000 / 4.010
  • Day's Range: 3.830 - 4.010
Type:  Equity
Market:  Egypt
ISIN:  EGS512O1C012 
Ibnsina Pharma 4.000 +0.050 +1.27%

ISPH Financial Summary

 
A brief financial summary of Ibnsina Pharma Co as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Ibnsina Pharma reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was EGP 7,853.66 million compared to EGP 4,928.36 million a year ago. Net income was EGP 59.45 million compared to EGP 29.23 million a year ago. Basic earnings per share from continuing operations was EGP 0.0005 compared to EGP 0.0002 a year ago.For the six months, sales was EGP 14,697.04 million compared to EGP 10,261.15 million a year ago. Net income was EGP 132 million compared to EGP 88.61 million a year ago. Basic earnings per share from continuing operations was EGP 0.0011 compared to EGP 0.0007 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ISPH Income Statement

Gross margin TTM 7.52%
Operating margin TTM 3.24%
Net Profit margin TTM 0.75%
Return on Investment TTM 6.41%
 Total Revenue  Net Income
Period Ending: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022
Total Revenue 6843.37 6453.09 5550.26 4928.36
Gross Profit 546.43 419.27 428.82 373.05
Operating Income 235 117.41 149.89 76.29
Net Income 72.55 52.99 30.99 29.23

ISPH Balance Sheet

Quick Ratio MRQ 0.49
Current Ratio MRQ 1.01
LT Debt to Equity MRQ 47.45%
Total Debt to Equity MRQ 900.88%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022
Total Assets 15323.15 12863.79 12354.8 11626.93
Total Liabilities 13991.11 11603.92 11108.44 10249.42
Total Equity 1332.04 1259.88 1246.36 1377.52

ISPH Cash Flow Statement

Cash Flow/Share TTM 0.18
Revenue/Share TTM 27.02
Operating Cash Flow  -4.17%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -542.09 613.77 995.77 -395.74
Cash From Investing Activities -52.53 -15.61 -1102.03 317.58
Cash From Financing Activities 621.03 -532.77 249.55 167.74
Net Change in Cash 26.41 65.39 142.47 90.4
* In Millions of EGP (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ISPH Comments

Write your thoughts about Ibnsina Pharma Co
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email